# Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)

> **NCT00289991** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 489 (actual)

## Conditions studied

- Antifungal Prophylaxis of Invasive Fungal Infections

## Interventions

- **DRUG:** Itraconazole
- **DRUG:** Vfend - voriconazole

## Key facts

- **NCT ID:** NCT00289991
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 489 (ACTUAL)
- **Last updated:** 2015-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00289991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00289991, "Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00289991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*